Evidence map›Paper›PMID 34191930›Full record

ArticleBreast care (Basel, Switzerland)2020

Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy.

Maria Cristina Leonardi, Emilia Montagna, Viviana Enrica Galimberti, Mattia Zaffaroni, Damaris Patricia Rojas, Samantha Dicuonzo, Maria Alessia Zerella, Anna Morra, Claudia Sangalli, Sara Gandini and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Breast care (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Delayed presentation of inflammatory breast carcinoma during the COVID-19 pandemic.European surgery : ACA : Acta chirurgica Austriaca · 2022
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Maria Cristina LeonardiDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Emilia MontagnaDivision of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Viviana Enrica GalimbertiDivision of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Mattia ZaffaroniDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Damaris Patricia RojasDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Samantha DicuonzoDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Maria Alessia ZerellaDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Anna MorraDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Claudia SangalliDivision of Data Management, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Sara GandiniDepartment of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Marco ColleoniDivision of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Paolo VeronesiDivision of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Marianna Alessandra GerardiDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Daniela AlterioDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Roberta LazzariDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Massimo Sarra FioreDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Giammaria BufiDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Federica CattaniUnit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Fabrizio MastrilliMedical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Roberto OrecchiaScientific Direction, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
European Institute of Oncology · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDuring the COVID-19 pandemic, Lombardy (Northern Italy) Regional Health Council created hubs for cancer care, meant to be SARS-CoV-2-free pathways for cancer patients. The workflow of breast cancer (BC) radiotherapy (RT) in one of the hubs is presented here.

methodsCandidates to adjuvant RT during the pandemic peak of March-April 2020 were compared to those treated in the same period of 2019, and patient volume, deferral rate, and type of RT were analyzed. Statistics were calculated with χ

resultsIn March-April 2020 the BC patient volume increased by 28% compared to the same period in 2019 (scheduled patients: 175 vs. 137) and amid travel restrictions it was kept high (treated patients: 136 vs. 133), mainly due to an influx from across Lombardy. RT schemes basically did not change, being already centered on hypofractionation. The increase of median time (67 vs. 74.5 days in 2019 and 2020, respectively) to the commencement of RT for low-risk patients was clinically negligible yet statistically significant (

conclusionThe workload for BC was high during the pandemic peak. Hubs allowed the continuation of oncologic treatments, while mitigating the strain on frontline COVID-19 hospitals.

Indexed as

Breast cancerCOVID-19HubOncologic carePandemic

Identifiers

PMID34191930
PMCPMC7801963
OpenAlexW3121150001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.